AC Immune SA (STU:IMR)
€ 3.765 -0.3 (-7.49%) Market Cap: 376.55 Mil Enterprise Value: 270.11 Mil PE Ratio: 0 PB Ratio: 2.48 GF Score: 58/100

AC Immune SA at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 12:00PM GMT
Release Date Price: €3.08 (-1.72%)
Lucy Codrington
Jefferies LLC - Analyst

Okay. Good morning and welcome to day-2 of the Jefferies New York Healthcare Conference. My name is Lucy Codrington; I'm one of the European pharma and biotech analysts based in London. It is my pleasure to introduce Andrea Pfeifer, the CEO of AC Immune. Andrea is going to kick off with a short presentation and then we're going to move to a fireside chat. So with that, I'll hand over to Andrea.

Andrea Pfeifer
AC Immune SA - Co-Founder, CEO & Director

Yeah. Good morning. I'm very happy that you could join. I'm pleased to be here in person and present to you AC Immune, a company focusing on the precision medicine in neurodegenerative diseases. Today, I will give you a short update on our pipeline, speak about very focused growth initiatives, and give you an insight into the clinical program in diagnostic and therapeutics and then end up with a short review of our milestones remaining for this year.

This is a disclaimer. So just as a reminder, AC Immune's value is really related to a pipeline, which is one of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot